Kyntra Bio
Kyntra Bio's revenue fell 78.3% to $6 million in fiscal 2025. Its operating margin was −712.7%, down from −507.8% a year earlier. Free cash flow was −$5 million. The diluted share count rose 1.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 405 | 422 | 204 | 50 | 89 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −268.4x | −209.1x | −39.9x | −18.2x | −5.2x |
| Current ratio | 2.1x | 1.8x | 1.5x | 1.5x | 3.4x |
| Quick ratio | 2.0x | 1.6x | 1.4x | 1.4x | 3.3x |
Cash flow
Projections
Project Kyntra Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $19,852 of Kyntra Bio shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 14, 2026 | Thane WettigCEO, Director | Bought | 2,800 | $7.09 | $19,852 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −745.2% | −503.5% | −153.0% |
| Altman Z'' | −17.86 | −32.03 | −45.41 |
| Accruals ratio | 6.0% | 28.3% | 112.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Kyntra Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Kyntra Bio | FY25 | −78.3% | −712.7% | −74.7% | — | — | — | |
| Immunome | FY25 | −23.2% | −3,228.8% | −2,890.1% | — | — | — | Compare |
| Ovid Therapeutics | FY25 | 1,181.3% | −585.2% | −528.6% | — | — | — | Compare |
| Xenon Pharmaceuticals | FY25 | — | −4,974.3% | −3,732.2% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 183 | 131 | 213 | 257 | 176 | 235 | 141 | 47 | 30 | 6 |
| Revenue growth | 1.3% | −28.5% | 62.6% | 20.5% | −31.3% | 33.5% | −40.2% | −66.7% | −36.7% | −78.3% |
| Gross profit | — | — | — | 255 | 167 | 222 | 120 | 43 | 14 | 6 |
| Research and development | 187 | 196 | 236 | 209 | 253 | 387 | 297 | 266 | 96 | 24 |
| Operating income | −50 | −117 | −87 | −89 | −192 | −288 | −301 | −323 | −150 | −46 |
| Net income | −58 | −121 | −86 | −77 | −189 | −290 | −294 | −284 | −48 | 184 |
| Diluted EPS (US$) | −23.25 | −41.50 | −25.75 | −22.25 | −52.75 | −78.50 | −78.50 | −73.00 | −11.89 | 45.37 |
| Diluted shares (millions) | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Cash flow | ||||||||||
| Cash from operations | 7 | −66 | −76 | −79 | 82 | −82 | −146 | −315 | −138 | −5 |
| Capital expenditure | 1 | 8 | 8 | 6 | 4 | 5 | 4 | 2 | 0 | 0 |
| Free cash flow | 6 | −75 | −84 | −84 | 78 | −87 | −150 | −318 | −138 | −5 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 32 | 38 | 52 | 66 | 73 | 71 | 66 | 51 | 25 | 7 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 253 | 736 | 621 | 534 | 686 | 405 | 422 | 204 | 50 | 89 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 470 | 899 | 881 | 857 | 827 | 774 | 610 | 424 | 214 | 120 |
| Total liabilities | 294 | 351 | 352 | 322 | 385 | 545 | 612 | 586 | 398 | 115 |
| Shareholders' equity | 156 | 528 | 509 | 516 | 422 | 209 | −21 | −204 | −226 | −30 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | 99.5% | 95.0% | 94.5% | 85.6% | 91.5% | 47.5% | 91.4% |
| Operating margin | −27.3% | −89.5% | −40.7% | −34.8% | −108.8% | −122.6% | −213.9% | −689.5% | −507.8% | −712.7% |
| Net margin | −31.7% | −92.3% | −40.6% | −30.0% | −107.4% | −123.2% | −208.7% | −607.3% | −160.6% | 2,848.6% |
| Free cash flow margin | 3.2% | −57.3% | −39.5% | −32.9% | 44.0% | −37.1% | −106.3% | −678.5% | −466.8% | −74.7% |
| Rule of 40 (growth + FCF margin) | 4.5% | −85.8% | 23.1% | −12.4% | 12.7% | −3.7% | −146.5% | −745.2% | −503.5% | −153.0% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −34.8% | −35.3% | −16.7% | −15.0% | −40.4% | −91.9% | −312.9% | — | — | — |
| Return on assets | −12.3% | −17.7% | −9.7% | −8.9% | −22.5% | −36.2% | −42.4% | −55.0% | −14.9% | 109.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |